Overview Dividends

(IMVT) Immunovant - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45258J1025

Monoclonal Antibodies, Autoimmune Disease, IMVT-1402, Batoclimab

EPS (Earnings per Share)

EPS (Earnings per Share) of IMVT over the last years for every Quarter: "2020-09": -0.25, "2020-12": -0.32, "2021-03": -0.29, "2021-06": -0.31, "2021-09": -0.35, "2021-12": -0.36, "2022-03": -0.41, "2022-06": -0.35, "2022-09": -0.41, "2022-12": -0.49, "2023-03": -0.46, "2023-06": -0.57, "2023-09": -0.45, "2023-12": -0.36, "2024-03": -0.52, "2024-06": -0.6, "2024-09": -0.74, "2024-12": -0.76, "2025-03": -0.64, "2025-06": -0.71, "2025-09": -0.73,
EPS Growth (3y CAGR): -37.93%
EPS Trend (3y Corr): -77.2%
Last SUE: -0.26σ
Qual. Beats: 0

Revenue

Revenue of IMVT over the last years for every Quarter: 2020-09: 0, 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 1.5, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0.16, 2025-06: 0, 2025-09: 0,
Revenue Growth (3y CAGR): 0.00%
Revenue Trend (3y Corr): -0.3%
Last SUE: 0.00σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 55.0%
Value at Risk 5%th 79.3%
Relative Tail Risk -12.34%
Reward TTM
Sharpe Ratio -0.05
Alpha -24.16
Character TTM
Hurst Exponent 0.554
Beta 1.083
Beta Downside 1.071
Drawdowns 3y
Max DD 69.88%
Mean DD 32.11%
Median DD 31.26%

Description: IMVT Immunovant November 09, 2025

Immunovant, Inc. (NASDAQ: IMVT) is a clinical-stage biotech that builds monoclonal antibodies targeting B-cell pathways for autoimmune indications. Its lead pipeline includes IMVT-1402, a CD40-targeted antibody being explored in Graves’ disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), cutaneous lupus erythematosus, and Sjögren’s disease, and batoclimab, which is in development for myasthenia gravis, CIDP, and thyroid eye disease. The firm was spun out of Roivant Sciences in 2018 and is headquartered in New York.

Key quantitative signals (as of the most recent 10-Q filing) show a cash runway of roughly $140 million, enough to fund ongoing Phase 2 trials through late 2025, assuming no major cost overruns. The autoimmune market is expanding at a compound annual growth rate of ~ 7 % (2023-2030), driven by aging demographics and increasing willingness to adopt biologics, which underpins demand for novel agents like IMVT-1402. However, the competitive landscape is dense-major players such as Roche (Roche-approved anti-CD40 antibodies) and AbbVie are advancing similar mechanisms, introducing execution risk that could compress market share if Immunovant’s trials do not meet primary endpoints.

For a data-driven, risk-adjusted assessment of IMVT’s upside potential, the ValueRay platform offers a granular model that can help you evaluate the trade-off between clinical milestones and valuation metrics.

IMVT Stock Overview

Market Cap in USD 4,161m
Sub-Industry Biotechnology
IPO / Inception 2019-06-21
Return 12m vs S&P 500 -24.3%
Analyst Rating 4.64 of 5

IMVT Dividends

Currently no dividends paid

IMVT Growth Ratios

Metric Value
CAGR 3y 19.21%
CAGR/Max DD Calmar Ratio 0.27
CAGR/Mean DD Pain Ratio 0.60
Current Volume 1885.7k
Average Volume 1566.7k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-464.7m TTM) > 0 and > 6% of Revenue (6% = 9600 TTM)
FCFTA -0.74 (>2.0%) and ΔFCFTA -21.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 318.9k% (prev 29.4k%; Δ 289.6kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.74 (>3.0%) and CFO -431.0m > Net Income -464.7m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 9.07 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (173.6m) change vs 12m ago 18.55% (target <= -2.0% for YES)
Gross Margin -78.75% (prev 80.60%; Δ -159.4pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.03% (prev 0.29%; Δ -0.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -19.75 (EBITDA TTM -486.7m / Interest Expense TTM -24.7m) >= 6 (WARN >= 3)

Altman Z'' -33.18

(A) 0.88 = (Total Current Assets 573.5m - Total Current Liabilities 63.3m) / Total Assets 583.0m
(B) -2.55 = Retained Earnings (Balance) -1.49b / Total Assets 583.0m
warn (B) unusual magnitude: -2.55 — check mapping/units
(C) -0.89 = EBIT TTM -487.1m / Avg Total Assets 549.3m
(D) -23.48 = Book Value of Equity -1.49b / Total Liabilities 63.3m
Total Rating: -33.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 25.28

1. Piotroski 0.0pt
2. FCF Yield -11.85%
3. FCF Margin data missing
4. Debt/Equity 0.00
5. Debt/Ebitda 1.07
6. ROIC - WACC (= -99.47)%
7. RoE -84.94%
8. Rev. Trend -0.29%
9. EPS Trend -77.16%

What is the price of IMVT shares?

As of November 23, 2025, the stock is trading at USD 22.59 with a total of 1,885,674 shares traded.
Over the past week, the price has changed by -4.84%, over one month by +17.47%, over three months by +52.22% and over the past year by -14.88%.

Is IMVT a buy, sell or hold?

Immunovant has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy IMVT.
  • Strong Buy: 10
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the IMVT price?

Issuer Target Up/Down from current
Wallstreet Target Price 38.5 70.3%
Analysts Target Price 38.5 70.3%
ValueRay Target Price 23.7 4.9%

IMVT Fundamental Data Overview November 17, 2025

Market Cap USD = 4.16b (4.16b USD * 1.0 USD.USD)
P/B = 8.0066
Beta = 0.556
Revenue TTM = 160.0k USD
EBIT TTM = -487.1m USD
EBITDA TTM = -486.7m USD
Long Term Debt = 98.0k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 98.0k USD (from shortTermDebt, last fiscal year)
Debt = 98.0k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -521.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.64b USD (4.16b + Debt 98.0k - CCE 521.9m)
Interest Coverage Ratio = -19.75 (Ebit TTM -487.1m / Interest Expense TTM -24.7m)
FCF Yield = -11.85% (FCF TTM -431.3m / Enterprise Value 3.64b)
FCF Margin = -269.6k% (FCF TTM -431.3m / Revenue TTM 160.0k)
Net Margin = -290.4k% (Net Income TTM -464.7m / Revenue TTM 160.0k)
Gross Margin = -78.75% ((Revenue TTM 160.0k - Cost of Revenue TTM 286.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 6.24 (Enterprise Value 3.64b / Total Assets 583.0m)
Interest Expense / Debt = 4148 % (Interest Expense 4.07m / Debt 98.0k)
Taxrate = -0.47% (negative due to tax credits) (594.0k / -125.9m)
NOPAT = -489.4m (EBIT -487.1m * (1 - -0.47%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 9.07 (Total Current Assets 573.5m / Total Current Liabilities 63.3m)
Debt / Equity = 0.00 (Debt 98.0k / totalStockholderEquity, last quarter 519.7m)
Debt / EBITDA = 1.07 (negative EBITDA) (Net Debt -521.9m / EBITDA -486.7m)
Debt / FCF = 1.21 (negative FCF - burning cash) (Net Debt -521.9m / FCF TTM -431.3m)
Total Stockholder Equity = 547.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -79.71% (Net Income -464.7m / Total Assets 583.0m)
RoE = -84.94% (Net Income TTM -464.7m / Total Stockholder Equity 547.1m)
RoCE = -89.02% (EBIT -487.1m / Capital Employed (Equity 547.1m + L.T.Debt 98.0k))
RoIC = -89.46% (negative operating profit) (NOPAT -489.4m / Invested Capital 547.1m)
WACC = 10.01% (E(4.16b)/V(4.16b) * Re(10.01%) + (debt cost/tax rate unavailable))
Discount Rate = 10.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.61%
Fair Price DCF = unknown (Cash Flow -431.3m)
EPS Correlation: -77.16 | EPS CAGR: -37.93% | SUE: -0.26 | # QB: 0
Revenue Correlation: -0.29 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for IMVT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle